{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:44:20Z","timestamp":1742391860333},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.intimp.2013.05.029","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T08:45:29Z","timestamp":1371631529000},"page":"178-183","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30days with MK-7123, a selective CXCR2 antagonist"],"prefix":"10.1016","volume":"17","author":[{"given":"Michael","family":"Seiberling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Kamtchoua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Stryszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald B.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sauzanne","family":"Khalilieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2013.05.029_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/thx.51.3.267","article-title":"Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils","volume":"51","author":"St\u0103nescu","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2013.05.029_bb0010","doi-asserted-by":"crossref","first-page":"151S","DOI":"10.1378\/chest.121.5_suppl.151S","article-title":"Neutrophils and the pathogenesis of COPD","volume":"121","author":"Stockley","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2013.05.029_bb0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.pathol.4.110807.092145","article-title":"The pathology of chronic obstructive pulmonary disease","volume":"4","author":"Hogg","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1183\/09031936.00186109","article-title":"Neutrophils in chronic inflammatory airway diseases: can we target them and how?","volume":"35","author":"Gernez","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.intimp.2013.05.029_bb0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/thorax.56.6.432","article-title":"Enhanced neutrophil response in chronic obstructive pulmonary disease","volume":"56","author":"Noguera","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.intimp.2013.05.029_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00151829-200403030-00003","article-title":"Role of neutrophils in mucus hypersecretion in COPD and implications for therapy","volume":"3","author":"Kim","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.intimp.2013.05.029_bb0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pharmthera.2009.06.004","article-title":"Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis","volume":"124","author":"Simpson","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2013.05.029_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pharmthera.2008.10.005","article-title":"CXCR2 antagonists for the treatment of pulmonary disease","volume":"121","author":"Chapman","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2013.05.029_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fimmu.2012.00263","article-title":"CXCR2: from bench to bedside","volume":"3","author":"Stadtmann","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0050","doi-asserted-by":"crossref","first-page":"L322","DOI":"10.1152\/ajplung.00039.2005","article-title":"Role of CXCR2 in cigarette smoke-induced lung inflammation","volume":"289","author":"Thatcher","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0055","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/jm0609622","article-title":"Discovery of 2-hydroxy-N, N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2\/CXCR1 receptor antagonist","volume":"49","author":"Dwyer","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.intimp.2013.05.029_bb0060","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.119040","article-title":"A novel, orally active CXCR1\/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation","volume":"322","author":"Chapman","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.intimp.2013.05.029_bb0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/jpet.106.118927","article-title":"Pharmacological characterization of Sch527123, a potent allosteric CXCR1\/CXCR2 antagonist","volume":"322","author":"Gonsiorek","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.intimp.2013.05.029_bb0070","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.intimp.2013.05.029_bb0075","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.93.13.6682","article-title":"Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2","volume":"93","author":"Jones","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2013.05.029_bb0080","first-page":"613s","article-title":"Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy volunteers [abstract]","volume":"30","author":"Khalilieh","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.intimp.2013.05.029_bb0085","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1172\/JCI41649","article-title":"CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow","volume":"120","author":"Eash","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2013.05.029_bb0090","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2125.2011.03968.x","article-title":"SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans","volume":"72","author":"Lazaar","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0095","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.intimp.2013.05.029_bb0100","first-page":"145","article-title":"International union of pharmacology. XXII. Nomenclature for chemokine receptors","volume":"52","author":"Murphy","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.intimp.2013.05.029_bb0105","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.intimp.2013.05.029_bb0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jcbfm.2009.240","article-title":"Role of chemokines in CNS health and pathology: a focus on the CCL2\/CCR2 and CXCL8\/CXCR2 networks","volume":"30","author":"Semple","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"issue":"RR-7","key":"10.1016\/j.intimp.2013.05.029_bb0115","first-page":"1","article-title":"Bell BP for the Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.intimp.2013.05.029_bb0125","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1086\/516512","article-title":"Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men","volume":"176","author":"Neilsen","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.intimp.2013.05.029_bb0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0168-8278(97)80039-6","article-title":"Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults","volume":"26","author":"Chen","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/(SICI)1096-9071(199602)48:2<147::AID-JMV5>3.0.CO;2-9","article-title":"Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children","volume":"48","author":"Richtmann","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0140","series-title":"Immunity: the immune response in infectious and inflammatory disease","first-page":"172","author":"DeFranco","year":"2007"},{"key":"10.1016\/j.intimp.2013.05.029_bb0145","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI108517","article-title":"Neutrophil kinetics in man","volume":"58","author":"Dancey","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2013.05.029_bb0150","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.4049\/jimmunol.181.8.5183","article-title":"Homeostatic regulation of blood neutrophil counts","volume":"181","author":"von Vietinghoff","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8s","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SPC.0b013e32832ea6ae","article-title":"Advances in the treatment of neutropenia","volume":"3","author":"Dale","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.intimp.2013.05.029_bb0165","unstructured":"Finley RS, LaCivita CL, Lindley CM. Adverse effects of chemotherapy. In: Adverse Effects of Chemotherapy (Applied Therapeutics, The clinical use of drugs, 6th edition, Young LY, MA Koda-Kimble, eds.), 1995;91\u20131 to 91\u201328."},{"key":"10.1016\/j.intimp.2013.05.029_bb0170","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2013.05.029_bb0175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-011-1769-7","article-title":"The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia","volume":"69","author":"Hansson","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913002300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576913002300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T05:50:28Z","timestamp":1539582628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576913002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1567576913002300"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2013.05.029","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30days with MK-7123, a selective CXCR2 antagonist","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2013.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}